NAD+

NAD+ is a dinucleotide consisting of nicotinamide and adenosine moieties linked through a pyrophosphate bridge. The nicotinamide ring is the redox-active center, accepting a hydride at the C4 position to form the reduced cofactor NADH during oxidoreductase-catalyzed reactions. The molecule's interaction profile in the literature spans hundreds of NAD+-dependent enzymes — dehydrogenases, the sirtuin deacetylase family, PARP polymerases, CD38 NADases, and the ADP-ribosyltransferases — each of which engages NAD+ at a defined active-site geometry. Pharmacokinetic descriptors documented in published animal-model investigations include rapid intracellular turnover and extracellular catabolism by ectoenzymes such as CD38. Interaction profile in published work centers on hydride-transfer catalysis, ADP-ribose donation, and nicotinamide salvage-pathway intersection. All activity descriptors here are framed as documented in published research.

Experimental domains documented in the published literature include oxidoreductase enzyme-kinetic studies, sirtuin-family deacetylase assays, PARP-pathway research in DNA-damage-response paradigms, CD38 NADase enzymology, mitochondrial-function research probing the NAD+/NADH ratio, cellular-aging investigations of NAD+ depletion, structure-activity work on NAD+-mimetic enzyme inhibitors, mass-spectrometry analytical-method development where NAD+ serves as a reference standard, and biosensor-development paradigms using NAD+/NADH redox cycling. Investigators have also characterized NAD+ in plant and microbial-redox biology and in metabolic-flux analysis across cellular compartments. Use in laboratory research extends to the foundational coenzyme reference standard role. The reference material is supplied for these and equivalent in-vitro and analytical experimental contexts only, with no associated guidance for human, clinical, or veterinary application.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by UV-spectrophotometry for the characteristic 260 nm and 340 nm absorbance ratios that distinguish oxidized NAD+ from reduced NADH. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside molecular-ion confirmation by mass spectrometry against the C21H27N7O14P2 empirical formula. The oxidized-versus-reduced state is confirmed by absorbance-ratio assay when included in the release specification — a critical parameter given the redox-cycling chemistry of the molecule. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized or solid reference standard should be held at −20°C (or −80°C for extended preservation of redox state) in its sealed, light-protected, oxygen-restricted container until ready for analytical use. NAD+ is sensitive to humidity, light, and prolonged warming — exposure can drive hydrolysis of the pyrophosphate bridge and accumulation of degradation products. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation. Reconstitution for in-vitro experimental use is typically performed in cold buffered solution at neutral or slightly acidic pH (NAD+ is more stable in acid than in alkaline conditions). Once reconstituted, store at 2–8°C and use promptly. Avoid repeated freeze-thaw cycles. These handling parameters reflect general best-practice for redox-active coenzyme reference standards and do not constitute preparation guidance for human or veterinary application.